The Moderna vaccine faces stiff competition from RSV vaccines Arexvy and Abrysvo ... the industry’s 8% decline, as seen in the chart below. During this timeframe, the stock also underperformed ...

Analysts had expected sales of $13 million for the RSV vaccine, according to StreetAccount ... stock market to make a move or break down, says chart analyst Analysts speculate selling by Buffett ...

Good morning. Covid became a pandemic five years ago. Today we’re covering how it continues to shape American society. , a ...

With 250 deaths in the state, including King County children, the health department says the influenza-like activity remains ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium Blue Lake Biotechnology, Inc., a clinical-stage ...

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free RSV vaccine ahead of the winter. By the end of November 2024 ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...

Since last September, people aged 75 to 79 have been eligible to come forward for a free vaccine to protect them from RSV. Pregnant women are also offered the vaccine from 28 weeks into their ...